Photo of Aditya  Bardia, MBBS, MPH

Aditya Bardia, MBBS, MPH


Accepting New Patients





Centers & Specialties

Cancer Center

Clinical Interests
  • Breast cancer
  • Targeted therapies
Medical Education
  • MBBS, All India Institute of Medical Sciences
  • MPH, University of Iowa College of Public Health
  • Residency, All India Institute of Medical Sciences|Residency, Mayo Clinic
  • Fellowship, The Johns Hopkins Hospital
Board Certifications
  • Internal Medicine
  • Medical Oncology
Foreign Languages
  • Hindi
  • Boston: Massachusetts General Hospital
Existing Patients
Patient Gateway
Insurances Accepted
  • Aetna Health Inc.
  • AllWays Health (NHP) - ACD
  • AllWays Health (NHP) - PBO
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Provider Gender


Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.

Research & Publications


View my most recent publications at PubMed

Select Publications:

  • Bardia A, Hartmann LC, et al. Leisure time physical activity & risk of postmenopausal breast cancer. Arch Intern Med. 2006;166:2478-83.
  • Bardia A, Barton DL, et al. Efficacy of complementary & alternative medicine therapies in relieving cancer pain: Systematic Review. J Clin Oncol. 2006;24:5457-64.
  • Bardia A, Ebbert JO, et al. Association of aspirin & other NSAID use with cancer incidence and mortality among post menopausal women. J Natl Cancer Inst. 2007;99(11):881-9.
  • Bardia A, Stearns V. Personal Breast. Breast Cancer Res Treat. Editorial. 2010;120(2):437-9.
  • Bardia A, Stearns V. Personalized Tamoxifen. Clin Cancer Res. Editorial. 2010;16(17):4308-10.

News & Events


55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-726-6500
Phone 2: 617-724-4800
Fax: 617-643-0589

Back to Top